Abstract:Microorganisms from new sources, such as those from extreme terrestrial environments and marine ecosystems, as well as those in association with mammals, invertebrates, and plants, hold great promise for the discovery of novel drugs. High-throughput miniaturized culture methods may facilitate the culture of the vast majority of uncultivated microorganisms. Metabolomics and metabologenomics enable high-throughput screening of natural products from diverse environmental samples. Large-scale genome mining offers unprecedented opportunities for exploitation of uncharacterized biochemical pathways embedded in cultivated and as-yet-uncultivated microorganisms. Pathway refactoring represents a versatile strategy for the discovery, combinatorial biosynthesis, and titer improvement of new bioactive natural products. The widespread emergence of antibiotic-resistant pathogens poses a severe threat to public health. This problem becomes even worse with a coincident decline in the supply of new antibiotics. Conventional bioactivity-guided natural product discovery has failed to meet the urgent need for new antibiotics, largely due to limited resources and high rediscovery rates. Recent advances in cultivation techniques, analytical technologies, and genomics-based approaches have greatly expanded our access to previously underexploited microbial sources. These strategies will enable us to access new reservoirs of microorganisms and unleash their chemical potentials, thus opening new opportunities for the discovery of next-generation drugs to address the growing concerns of antimicrobial resistance. The widespread emergence of antibiotic-resistant pathogens poses a severe threat to public health. This problem becomes even worse with a coincident decline in the supply of new antibiotics. Conventional bioactivity-guided natural product discovery has failed to meet the urgent need for new antibiotics, largely due to limited resources and high rediscovery rates. Recent advances in cultivation techniques, analytical technologies, and genomics-based approaches have greatly expanded our access to previously underexploited microbial sources. These strategies will enable us to access new reservoirs of microorganisms and unleash their chemical potentials, thus opening new opportunities for the discovery of next-generation drugs to address the growing concerns of antimicrobial resistance. the ability of microbes, such as bacteria, viruses, fungi, and parasites, to resist the effects of antimicrobials that once could successfully treat them. genes responsible for the biosynthesis of specialized metabolites are usually grouped together on contiguous stretches of DNA to form biosynthetic gene clusters. DNA that is extracted directly from a variety of environmental samples, such as soil, water, and even air. a large-scale screening that is carried out at the whole genome level. a public online platform for analysis of tandem mass spectrometry (MS/MS) data that enables rapid dereplication of the MS/MS data generated against a public or user-curated reference library of mass spectra. a high-throughput method for identifying elicitors of silent gene clusters. This approach starts with the introduction of a reporter gene into the BGC of interest, allowing a rapid read-out for its expression. Small molecule libraries are then screened to identify candidate elicitors. a scientific method relevant to the fields of chemistry and biology, in which hundreds of thousands of samples are subjected to experimental tests. a method that combines genomics and metabolomics to discover new natural products and their BGCs. This approach starts with detection and classification of BGCs from sequenced microbial genomes. Similar BGCs are grouped into gene cluster families (GCFs), which are then correlated with liquid chromatography–mass spectrometry (LC–MS) metabolomics data. a comprehensive analysis of the entire set of metabolites in a biological sample or system to discover networks and interactions between metabolites. This approach mainly relies on mass spectrometry (MS), an analytical technique that ionizes chemicals and sorts the ions based on their mass-to-charge ratio that measures the masses within a sample. a technique that guides the molecular characterization based on the MS/MS fragmentation patterns of molecules, enabling the detection and visualization of large groups of metabolites. microbes resistant to multiple antimicrobials. chemical compounds or substances produced by organisms from natural sources. They are also referred to as secondary metabolites or specialized metabolites that are not directly involved in the normal growth, development, or reproduction of an organism. a rational strategy that applies a plug and play workflow to redesign and reconstruct target pathways for the production of natural products. microorganisms that cannot be cultivated using current culturing techniques in the laboratory.

Genomics-Driven Natural Product Discovery in Actinomycetes.

Mining Actinomycetes for Novel Antibiotics in the Omics Era: Are We Ready to Exploit This New Paradigm?

Targeting Bacterial Genomes for Natural Product Discovery

Next Generation Sequencing of Actinobacteria for the Discovery of Novel Natural Products

Targeted Genome Mining—From Compound Discovery to Biosynthetic Pathway Elucidation

Exploring and Exploiting Microbial Diversity Through Metagenomics for Natural Product Drug Discovery

Harnessing regulatory networks in Actinobacteria for natural product discovery

Genomics Approaches Decode Natural Products Synthesis

Genome mining and prospects for antibiotic discovery

Natural Products from Actinobacteria for Drug Discovery

Comparative genomics of actinomycetes with a focus on natural product biosynthetic genes

Exploring nature's battlefield: organismic interactions in the discovery of bioactive natural products

Recent Advances in Synthetic Biology Approaches to Optimize Production of Bioactive Natural Products in Actinobacteria

Next-Generation Drug Discovery to Combat Antimicrobial Resistance

Exploring a general multi-pronged activation strategy for natural product discovery in Actinomycetes

Harnessing the Biosynthetic Diversity of Actinomycetes: Discovery of Unique Natural Products through Comparative Genomic and Metabolic Analysis

Using Natural Products for Drug Discovery: the Impact of the Genomics Era

Biosynthesis of C-nucleoside antibiotics in actinobacteria: recent advances and future developments

The re-emergence of natural products for drug discovery in the genomics era

Recent advances in natural product discovery.

Natural and Engineered Biosynthesis of Nucleoside Antibiotics in Actinomycetes